1928 Diagnostics
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2022 | 2023 |
---|---|---|---|---|---|
Revenues | <1m | <1m | <1m | 2.0m | 2.0m |
% growth | - | (70 %) | 63 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
€50.0k | Grant | ||
* | N/A | €2.1m | Angel |
N/A | SEK15.0m | Early VC | |
Total Funding | €3.8m |
Recent News about 1928 Diagnostics
Edit1928 Diagnostics is a health technology startup that specializes in combating antibiotic resistance through advanced cloud-based software. The company operates in the healthcare sector, providing solutions primarily for hospitals and healthcare providers. Their main product is a bioinformatics analytics platform that uses whole genome sequencing (WGS) data to monitor, analyze, and control infections. This technology helps identify and characterize superbugs—bacteria that are resistant to multiple antibiotics—thus aiding in the tracking, controlling, and prevention of infectious disease outbreaks.
The core market for 1928 Diagnostics includes hospitals, healthcare systems, and quality care providers who are focused on infection control and epidemiology. These clients benefit from the company's high-precision detection and transmission analyses of dangerous pathogens, which are crucial for maintaining high standards of patient care and safety.
1928 Diagnostics operates on a subscription-based business model. Healthcare providers subscribe to their cloud-based software, gaining access to a suite of tools for infection control, including outbreak tracing, sample characterization, and resistance profiling. This subscription model ensures a steady revenue stream for the company while providing clients with continuous updates and support.
The company makes money by charging healthcare providers for access to its platform, which offers significant cost savings by preventing costly outbreaks and improving the overall efficiency of infection control measures. Additionally, the platform's ability to save the power of antibiotics by preventing the spread of resistant bacteria translates into long-term financial benefits for healthcare systems.
In summary, 1928 Diagnostics is at the forefront of using cloud-based technology to fight antibiotic resistance, serving healthcare providers with tools that enhance infection control and epidemiological tracking.
Keywords: Antibiotic resistance, cloud-based software, healthcare, infection control, bioinformatics, whole genome sequencing, superbugs, outbreak tracing, pathogen detection, healthcare savings.